|Day Low/High||16.96 / 16.98|
|52 Wk Low/High||3.02 / 17.05|
Synergy Pharmaceuticals is developing drugs to treat gastrointestinal disorders and diseases. The
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of...
In this era of turmoil, investors can take comfort in this sector.
Oil prices backtrack from Monday's bounce, but energy stocks shake it off. Instead, the sector gains more than 1% after several weeks of punishing losses.
Oil is back in the spotlight Tuesday as prices backtrack from Monday's bounce and move lower again.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Avanir...
The Rosen Law Firm announces that it is investigating the Board of Directors of Avanir Pharmaceuticals, Inc.
U.S. stocks book modest gains on Tuesday morning as domestic construction spending expands.
Levi & Korsinsky is investigating the Board of Directors of Avanir Pharmaceuticals, Inc.
The Japanese drugmaker is trying to shore up its product pipeline ahead of April 2015 when patents on its best-selling schizophrenia drug Abilify expire.
U.S. stock futures edge higher on Tuesday after a selloff among tech and retail names left all benchmark indices in the red a day earlier.
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a pre-market mover with heavy volume candidate
Avanir Pharmaceuticals (AVNR) will be purchased by Otsuka Holdings Co. for about $3.54 billion, a deal that gives the Japanese company new treatments for neurological conditions,
U.S. stock futures rise slightly; Avanir to be bought by Japan's Otsuka Pharmaceutical; Cypress to buy Spansion; Ford and GM to report monthly sales.
Shares of Avanir Pharmaceuticals (AVNR) fell after the FDA provided preliminary written feedback to the biopharmaceutical company regarding its New Drug Application (NDA) for its migraine treatment drug AVP-825.
Deutsche Bank initiated coverage of Avanir Pharmaceuticals (AVNR) with a 'buy' rating and a price target of $17.
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a post-market leader candidate
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.